These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2008-006831-10 Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c... 2016-09-26 bad-data
Listed as ongoing, but also has a completion date 2009-013157-15 A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca... 2018-08-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-013788-21 A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis 2016-09-26 bad-data
Listed as ongoing, but also has a completion date 2009-015476-98 LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio... 2018-07-26 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-016178-33 A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ... 2015-09-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-016244-39 A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks in patients with type 2 diabet... 2015-08-28 bad-data
Ongoing 2009-017661-34 An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-018197-66 Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par... 2014-10-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000392-14 A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w... 2016-09-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-001758-26 A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t... 2015-12-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-002380-24 LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-bas... 2017-12-27 bad-data
Ongoing 2011-002766-21 An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) not-yet-due
Listed as ongoing, but also has a completion date and reported results 2012-000095-42 A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies... 2016-09-15 bad-data
Reported results 2012-002271-34 A phase III, randomized, double-blind, parallel group study to evaluate 2015-03-13 due-trials
Listed as ongoing, but also has a completion date 2012-002487-27 A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients ≥ 65... 2017-04-28 bad-data
Reported results 2012-003533-41 A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio... 2015-03-11 due-trials
Reported results 2012-003535-27 A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu... 2015-03-11 due-trials
Listed as ongoing, but also has a completion date 2012-005201-48 Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with peme... 2018-08-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-002671-18 An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d... 2015-10-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-003201-26 A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl... 2017-06-05 bad-data
Listed as ongoing, but also has a completion date 2013-003444-24 Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls... 2018-10-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-004813-41 A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran e... 2016-10-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-005031-24 A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... 2017-10-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2013-005040-28 A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t... 2017-10-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-002275-28 A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ... 2017-03-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-005256-26 A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w... 2017-12-28 bad-data
Listed as ongoing, but also has a completion date 2015-000392-28 A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ... 2018-11-28 bad-data
Ongoing 2015-001750-15 A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active... not-yet-due
Reported results 2015-003529-33 A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impa... 2017-10-24 due-trials
Reported results 2015-003622-13 BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and 2017-09-04 due-trials
Reported results 2015-003623-65 655066/ABBV-006 (risankizumab)versus adalimumab in a randomized, double blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and... 2017-08-27 due-trials
Listed as ongoing, but also has a completion date 2015-004412-38 RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients with c... 2018-06-22 bad-data
Other 2016-000669-21 A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext... not-yet-due
Ongoing 2016-002971-91 A randomized, double-masked, placebo-controlled exploratory not-yet-due
Ongoing 2016-003403-66 An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD) not-yet-due
Ongoing 2017-003101-17 An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out... not-yet-due
Ongoing 2017-003131-11 Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i... not-yet-due
Ongoing 2017-004072-59 A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... not-yet-due
Ongoing 2017-004073-14 A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie... not-yet-due